HC Wainwright Issues Positive Outlook for BLFS Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – Equities researchers at HC Wainwright lifted their Q1 2025 earnings estimates for BioLife Solutions in a note issued to investors on Wednesday, March 5th. HC Wainwright analyst Y. Chen now anticipates that the medical equipment provider will earn ($0.02) per share for the quarter, up from their previous estimate of ($0.10). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.16) EPS.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.32. The business had revenue of $22.71 million during the quarter, compared to the consensus estimate of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter last year, the firm earned ($0.21) earnings per share.

Other analysts have also issued research reports about the company. KeyCorp increased their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Craig Hallum raised their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Northland Securities boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Benchmark reaffirmed a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Finally, TD Cowen boosted their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Price Performance

Shares of BLFS stock opened at $25.83 on Monday. The stock has a 50 day moving average price of $26.65 and a 200 day moving average price of $25.49. BioLife Solutions has a 52-week low of $14.84 and a 52-week high of $29.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The firm has a market capitalization of $1.21 billion, a P/E ratio of -24.37 and a beta of 2.04.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. acquired a new stake in BioLife Solutions in the fourth quarter valued at approximately $20,664,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of BioLife Solutions during the 4th quarter valued at $19,805,000. Point72 Asset Management L.P. acquired a new stake in shares of BioLife Solutions in the 4th quarter worth $11,113,000. Millennium Management LLC grew its stake in BioLife Solutions by 49.1% during the 4th quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after buying an additional 377,111 shares during the last quarter. Finally, Rockefeller Capital Management L.P. increased its position in BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock valued at $14,661,000 after buying an additional 262,504 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Insider Transactions at BioLife Solutions

In other news, EVP Aby J. Mathew sold 7,604 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the completion of the transaction, the executive vice president now directly owns 276,315 shares of the company’s stock, valued at approximately $7,551,688.95. The trade was a 2.68 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now owns 121,779 shares of the company’s stock, valued at $3,290,468.58. This trade represents a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,978 shares of company stock valued at $322,724. Company insiders own 2.20% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.